1st Quarter - Report
RIVENDELL GROUP LLP for GENENTECH
Firm
Client
Income
$30,000
Expenses
—
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 4710, 340B Pause Act, and issues relating generally to the 340B Drug Discount Program; issues relating to drug pricing policies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Medicare/Medicaid MMM
HR 4710, 340B Pause Act and other issues relating generally to the 340B Drug Discount Program; issues relating to Medicare and Medicaid coverage and a reimbursement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Pharmacy PHA
Prescription Drug User Fee Act reauthorization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LA and Chief Counsel, Rep. Bart Stupak; LA Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.